Neil Finlaysonis CEO of clinical stage immunotherapy company, Admedus Immunotherapies, which is developing treatments for genital herpes and Human Papilloma virus associated cancers. Neil has extensive experience in banking and finance, JVs, partnering and licensing, and in company formations. During his career, Neil has licensed technologies to national and international biotech and pharmaceutical companies and been instrumental in the formation of 17 start-up companies. He has previously held positions as Business Development Director of Bio Innovation SA, CEO of Vaccine Solutions Pty Ltd (co-owned by CSL Limited and the QIMR Berghofer), Founding Director of AbRegen Pty Ltd and Executive Officer of the Cooperative Research Centre for Vaccine Technology (a $42M joint venture).